Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moleculin Biotech (MBRX) Short term Debt (2017 - 2022)

Moleculin Biotech (MBRX) has 6 years of Short term Debt data on record, last reported at $86000.0 in Q4 2022.

  • For Q4 2022, Short term Debt fell 21.1% year-over-year to $86000.0; the TTM value through Dec 2022 reached $86000.0, down 21.1%, while the annual FY2022 figure was $86000.0, 21.1% down from the prior year.
  • Short term Debt reached $86000.0 in Q4 2022 per MBRX's latest filing, down from $110000.0 in the prior quarter.
  • Across five years, Short term Debt topped out at $6.9 million in Q2 2019 and bottomed at $78000.0 in Q4 2020.
  • Average Short term Debt over 5 years is $1.2 million, with a median of $117000.0 recorded in 2022.
  • Peak YoY movement for Short term Debt: soared 1748.24% in 2019, then crashed 98.55% in 2020.
  • A 5-year view of Short term Debt shows it stood at $180000.0 in 2018, then tumbled by 45.0% to $99000.0 in 2019, then dropped by 21.21% to $78000.0 in 2020, then skyrocketed by 39.74% to $109000.0 in 2021, then dropped by 21.1% to $86000.0 in 2022.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $86000.0 in Q4 2022, $110000.0 in Q3 2022, and $95000.0 in Q2 2022.